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pies to standard care in the management of venous leg ulcers (VLUs).
Methods: A three-state Markov model derived from the medical
literature was developed to estimate the comparative cost-
effectiveness of three CTPs in relation to VLU standard care. CTPs
evaluated in the study included extracellular matrix (ECM), human
skin equivalent (HSE), and living skin equivalent (LSE). The three
Markov states included unhealed, healed, and death. A 1-year time
horizon was used to determine the number of ulcer-free weeks and
the expected costs of therapies. The payer perspective was taken in
the analysis and only the direct costs of care were considered.
Sensitivity analyses were performed to gauge model parameter
uncertainty. Results: The expected costs for standard care,
ECM, HSE, and LSE VLU therapy were $6,132, $6,732, $10,638, and
$11,237, while the expected outcomes were 24, 31, 29, and 27 ulcer-
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incremental cost-effectiveness ratio for ECM therapy was $86 per
ulcer-free week. Sensitivity analysis did not alter ECM dominance.
Clinic visits and home health utilization exhibited the greatest
inﬂuence on cost. Conclusions: ECM is the most cost-effective CTP
when used in the management of VLUs as an adjunct to standard
care. These ﬁndings suggest that VLU standard care therapy with ECM
can yield potential cost savings and produce better outcomes than do
other CTPs.
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Venous leg ulcers (VLUs) are a common and debilitating chronic
condition, often associated with a prolonged healing trajectory and
frequent recurrence [1,2]. Long-term outcomes often involve recur-
rence [3,4]. Nelzen et al. [4] followed patients who had an open VLU
for 5 years and found that only 58% had healed, 38% had open
unhealed ulcers, and 4% had undergone amputation [4]. VLUs can
occur at any age but are more prevalent in the elderly population,
with prevalence accentuating with the increase in life expectancy
[5]. In the United States, VLUs affect up to 2.5 million patients per
year [6] and pose signiﬁcant clinical and economic challenges to
health systems, patients, providers, and the community. Despite
signiﬁcant improvements in wound care management, VLUs can
take months to heal; in addition, infections and cellulitis are
frequent complications, leading to substantial disability, impaired
quality of life, and considerable morbidity [7–9]. Although accurate
estimates remain elusive, the management of VLUs consumessigniﬁcant health care resources. VLUs are estimated to cost the
US health care system more than $1 billion annually [10], with the
greatest cost burden borne by Medicare [11]. In addition, VLUs
account for the loss of more than 2 million workdays per year [12].
Given the aging population, the projected VLU treatment-related
costs are likely to escalate substantially in the coming years.
Individuals with chronic venous insufﬁciency are at high risk
of developing VLUs [13]. Chronic venous insufﬁciency occurs
because of a complex chain of events resulting from venous
valvular dysfunction affecting the superﬁcial, perforator, or deep
veins [14,15]. Over time, this leads to venous hypertension and
small vessel damage, which eventually progresses to edema,
hemosiderin deposition, and low-grade tissue inﬂammation
[14,15]. As a consequence, the integrity of the skin is disrupted,
resulting in persistent venous ulceration for several months or
years despite good standard care [16,17].
Compression therapy is the standard care for the treatment of
VLUs; however, it is often insufﬁcient to heal VLUs in a timelyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3802manner. Applying compression bandages presses the distended
veins together from the outside, which enables the venous valves to
close again. Therefore, the leg muscles can squeeze the blood more
efﬁciently out of the veins, which improves the return transport of
blood to the heart. To assess the efﬁcacy of standard care for VLUs,
different types of compression bandaging have been evaluated in
various randomized controlled trials (RCTs) [18,19]. The Canadian
Bandaging Trial [18] found no signiﬁcant differences in the distri-
bution of cumulative healing times between the four-layer and
short-stretch bandaging (61% vs. 54% healed ulcers at 12 weeks,
respectively). In addition, the choice of bandage therapy (four-layer
or short-stretch) did not materially affect healing times, recurrence
rates, pain, or health-related quality of life. Because compression
therapies offer only moderate beneﬁt with recalcitrant VLUs, in
recent years, alternative avenues have explored advanced thera-
peutics using cellular and/or tissue-derived products (CTPs) such as
extracellular matrix (ECM; OASIS) [20], human skin equivalent (HSE;
Apligraf) [21–23], and living skin equivalent (LSE; Dermagraft) [24–
27]. Speciﬁcally, studies using CTPs focus on alleviating the stasis of
wounds stuck in the inﬂammatory phase by supplying various
biological factors, reducing levels of unwanted cytokines or
enzymes (such as matrix metalloproteinases), and/or creating a
temporary ECM (which results in granulation) [28].
Estimated costs to heal VLUs vary considerably and depend on
ulcer size. The longer it takes to heal an ulcer, the greater the
ﬁnancial burden to the health care system [29]. Controlled clinical
studies have shown that HSE is more economical and effective at
healing chronic VLUs than is standard care alone [30,31]. Schonfeld
et al. [31] reported that the estimated average direct cost (US dollars)
of care for VLUs treated with HSE was $12,807 compared with
$10,482 with Unna boot therapy; moreover, patients treated with
HSE had almost 3 additional healed months (4.60 vs. 1.75, respec-
tively). Kerstein et al. [30] reported in a systematic literature review
that the cost of 12-week wound care for a healing VLU ranged from
$1,873 to $ 15,053, which included some VLUs treated with HSE. The
cost-effectiveness of ECM and LSE is yet to be determined for the
management of VLUs. Given the anticipated increase in the
incidence of VLUs and the high costs of VLU-related care, it is
critical to carefully assess the comparative value of adjunct thera-
pies to standard care for the management of chronic VLUs. Thus,
the overall goal of the study was to develop a cost-effectiveness
model derived from a systematic literature review to compare ECM,
HSE, and LSE in adjunct to standard care compared with standard
care alone in the treatment of VLUs over a period of 1 year.
Methods
Systematic Literature Review
Literature Search
A systematic literature review was conducted searching for articles
published from 1985 to 2012 for the development of the economic
model. PubMed, Scopus, Cochrane, and Google Scholar databases
were used to retrieve published reports on wound or ulcer healing
outcomes and studies that detailed the costs, cost-effectiveness, or
resource utilization of CTPs used in the management of VLUs.
Nonindexed journals such as Wounds and Worldwide Wounds were
manually searched. The search was restricted to English language
articles. Searches also included meeting or conference abstracts,
presentations, research letters, and research articles.
Inclusion criteria
To be considered as useful sources of data for model input,
studies needed to have the following characteristics: CTPs had to be commercially available (Table 1); allograft
products grown in institutions for speciﬁc studies were
considered ineligible. Include VLUs with clinical and/or economic outcomes.
 Deﬁne VLUs as chronic (duration >12 weeks) [32].
 For outcome studies, include complete wound healing as an
outcome.
 For studies on costs of healing, resource utilization, or cost-
effectiveness, costs could be derived from commercial costs or
nationally based health care systems (e.g., Medicare in the
United States). If clinically based, be a comparative study deﬁned as any RCT,
cohort, case-control, cross-sectional, or quasi-experimental
design in which a treatment group is compared with a
standard care group or one treatment group is compared
against another.
The search terms or key words that were used for the review
are listed in Table 1. Studies that met eligibility criteria were
retrieved in full on the basis of the examination of the abstract. If
an abstract was not available, the document was retrieved to
examine relevancy. Studies that were rejected as irrelevant were
documented with a reason for rejection. Review articles were not
accepted as primary sources of material; however, they were
retrieved for the purpose of examining their bibliographies for
additional studies not identiﬁed in the initial literature search.
Six hundred and thirty-four reports were identiﬁed in the
medical literature as potential candidates for use in the analysis
(Fig. 1). After a review of the abstracts, 583 were excluded for
failing to meet the inclusion criteria. Fifty-one articles were
retrieved and reviewed in full with 41 rejected on full review. Of
the 10 studies that met the inclusion criteria, 5 were used to
populate the clinical outcomes of the Markov model [19,20,33–35]
and the remaining 5 were used to supply information on health
economic, resource utilization, and ulcer recurrence [10,36–39].
Where possible, resource utilization data were extracted from the
clinical literature. Otherwise resource utilization was based on
interviews with wound care specialists. After literature review
and evaluation, three CTPs were selected for analysis: ECM or
OASIS (Smith & Nephew Biotherapeutics, Fort Worth, TX), HSE or
Apligraf (Organogenesis, Inc., Canton, MA), and LSE or Dermagraft
(Shire Regenerative Medicine, Inc., San Diego, CA).
Transition Probabilities
Healing Rates
Wound state transition and ulcer recurrence probabilities are
presented in Table 2. Of the four clinical trials [20,33–35], three
reported clinical outcomes of ulcer healing at 12 weeks [20,34,35],
with one trial having outcomes up to 6 months [33]. The Box-
Muller transform method was used to generate random number
sampling from the reported means and SDs of the clinical trials
[40]. A one-way analysis of variance was conducted to assess
whether signiﬁcant baseline clinical and demographic differences
existed across the four trials in the treatment arms and standard
care arms. Wound surface area was not statistically different
among the three CTP trials (P¼0.58). The mean wound surface
area was 6.7  4.1 cm2 (95% conﬁdence interval 1.3–10.2). ECM had
the largest baseline wound surface area (10.2  1.5 cm2), and HSE
had the smallest baseline wound surface area (1.3  2.7 cm2). The
average wound duration at baseline ranged from 1.5 months to
2 years for all trials [20,33–35].
Standard care for the four clinical trials was compression
therapy. Treatment and regimen of compression therapy were
the same in the four trials because compression therapy is the
established standard care regimen for VLUs [16]. Wound surface
area for standard care was not statistically different between the
four trials (P¼0.46). The mean wound surface area was 8.6 cm2 
5.3 (95% conﬁdence interval 1.1–12.3). The incidence of healing
was similar in the standard care arms: 34% in ECM, 49% in HSE,
Fig. 1 – Trial ﬂow diagram showing retrieval and selection of
articles for model input.
Table 1 – Search terms used for systematic
literature review.*
Speciﬁc products Description
Alloskin Allograft derived from epidermal and
dermal cadaveric tissue
Apligraf or graftskin Living cell–based bilayered engineered
tissue derived from bovine type 1
collagen and human ﬁbroblasts and
keratinocytes derived from neonatal
foreskins
Cymetra Micronized
AlloDerm Tissue
Injectable form of AlloDerm
Regenerative Tissue Matrix
DermACELL or
ArthroFlex
Acellular human dermis product
Dermagraft Cryopreserved human ﬁbroblast-
derived engineered tissue substitute.
Fibroblasts obtained from human
newborn foreskin tissue
Endoform Extracellular matrix derived from
ovine forestomach
GammaGraft Irradiated cadaveric human skin
allograft
Graftjacket Human acellular dermal matrix
Integra Bilayer Matrix
Wound Dressing
Bilayer matrix composed of a porous
layer of cross-linked bovine tendon
collagen and glycosaminoglycan and
a semipermeable polysiloxane
(silicone) layer
MatriStem Extracellular matrix product derived
from porcine urinary bladder
tissue
OASIS Wound Matrix Extracellular matrix derived from
porcine small intestinal submucosa
PriMatrix Extracellular matrix dermal substitute
derived from fetal bovine dermis
collagen
TheraSkin Biologically active cryopreserved
human skin allograft with both
epidermis and dermis layers
*A single search in PubMed was conducted using the linked terms
up to March 6, 2012.
The following generic terms were searched separately with the
term “ulcer” or “ulcers” added; limits of humans and adults
older than 19 y were set:
 Acellular dermal matrix
 Artiﬁcial dermis
 Artiﬁcial skin
 Bilayer living skin or bilayered living skin
 Bilayer matrix or bilayered matrix
 Bioengineered skin
 Composite
 Dermal construct
 Dermal equivalent or dermal equivalents
 Dermal regeneration
 Dermal scaffold
 Dermal template
 Engineered skin
 Epidermal equivalent or epidermal equivalents
 Extracellular matrix
 Skin equivalent or skin equivalents
 Skin replacement or skin replacements
 Skin substitute OR skin substitutes
Finally, the same set of terms was combined with the terms “cost”
or “cost-effectiveness” or “resource utilization”; in addition, the
term “venous ulcers” was searched in combination with the
terms “cost” or “cost-effectiveness” or “resource utilization.”
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at baseline ranged from 2 months to longer than 2 years for all
trials [20,33–35]. Because wound characteristics were not statisti-
cally different, patients from the standard care arm in Mostow
et al. [20] were selected as a reference. Patients’ demographic
characteristics in each standard care arm were similar, with
mean ages of 62, 60, 67, and 62 years, respectively. Most of the
patients were women in all but one study (64%, 51%, 54%, and
38%, respectively).
To extrapolate outcomes to 1 year, it was assumed that
healing rates should be similar among CTPs after 12 weeks, and
thus, in this study, the data from the venUS I trial [19] (speciﬁcally
from the four-layer bandage standard care arm) were adopted to
extrapolate healing trajectories beyond 12 weeks for the standard
care, ECM, and LSE cohorts [20,34,35] and beyond 6 months for
the HSE cohort [33]. Based on an analysis of wound trajectory
data from the venUS I trial [19], probabilities of healing were
simpliﬁed by calculating them for 12- and 26-week periods for
each of the four comparative therapies assessed with the Markov
model. If a wound did not heal, it remained in the unhealed state.Ulcer recurrence
Ulcer recurrence was deﬁned as a wound that had healed and
reopened (i.e., moving from the healed to the unhealed state).
Currently, there is no evidence available indicating that CTPs
either increase or decrease ulcer recurrence; therefore, the venUS
I trial [19] data were selected because the other RCTs used in
model inputs were too short in duration to provide adequate
Table 2 – Transition probabilities and percent occurrence.
Transition probabilities % Cycle transition
probability
Source
SC healing rate
Weeks 1–12 34 0.034 Mostow et al. [20]
Weeks 13–26 55 0.03 venUS I trial [19]
Weeks 27–52 65 0.012 venUS I trial [19]
ECM þ SC healing rate
Weeks 1–12 55 0.0644 Mostow et al. [20]
Weeks 13–26 77 0.03 venUS I trial [19]
Weeks 27–52 87 0.012 venUS I trial [19]
HSE þ SC healing rate
Weeks 1–12 57 0.068 Falanga et al. [33]
Weeks 13–26 63 0.007 Falanga et al. [33]
Weeks 27–52 10 0.012 venUS I trial [19]
LSE þ SC healing rate
Weeks 1–12 43 0.0458 Krishnamoorthy et al. [34] and Omar
et al. [35]
Weeks 13–26 65 0.03 venUS I trial [19]
Weeks 27–52 75 0.012 venUS I trial [19]
Ulcer recurrence
Weeks 1–12 9.5 0.0079 venUS I trial [19]
Weeks 13–52 4.5 0.001125 venUS I trial [19]
All-cause mortality 0.022 0.00022 Centers for Disease Control and
Prevention for 2005 for persons aged
60–64 y [41]
Percent occurrence for unhealed cost calculations
Hospitalization rate for DRG*
571: Skin debridement with CC 10 0.10 Olin et al. [11]
602: Cellulitis with major CC 1 0.05 Guest et al. [37]
603: Cellulitis without major CC 4 0.05 Sibbald et al. [38]
593: Skin ulcers with CC 10 0.10 Sibbald et al. [38]
Prescription pain drugs†
Amitriptyline 40 0.40 Woo et al. [39]
Gabapentin 10 0.10 Wound care expert
Hydrocodone 5 0.05 Wound care expert
Debridement rate
Weeks 1–12 12.5 0.125 Guest et al. [37]
Home health 25 0.25 Olin et al. [11] and Mostow et al. [20]
CC, complications and comorbidities; DRG, diagnostic-related group; ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin
equivalent; SC, standard care.
* Hospitalizations, debridements, prescription pain drugs, and home health visits occur only during the unhealed state.
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considered for ulcer recurrence (e.g., the Canadian Bandaging
Trial [18]), the venUS I trial was chosen because the primary
end point was complete healing of all the ulcers on the trial leg
[19].
The venUS I trial [19] reported that the incidence of ulcer
recurrence after 12 months was 13.1% in the four-layer bandage
group (eg, Profore) compared with 25.4% in the multilayer short-
stretch bandage group (wool padding or cotton bandages). For
weeks 1 to 11, the percentage of recurrence was 9.5% and 4.5% for
weeks 12 to 52 in the venUS I trial; therefore, the weekly
probability of ulcer recurrence was set at 0.0079 for all groups
for weeks 1 to 11 and 0.001125 for weeks 12 to 52.Death
The weekly probability of death per cycle set to 0.00022 based on
Centers for Disease Control and Prevention data for 2005 in which
the mortality rate (all causes) for the 60- to 64-year-old age group
in the United States (a common age group for venous ulcer
studies) was 0.0114 in 2005 [41].Economic Analysis
A Markov simulation model used the articles from the systematic
literature review to determine the cost-effectiveness of the three
commercially available CTPs as an adjunct to standard care
relative to standard care alone. The three Markov states included
unhealed, healed, and death. The Markov model provides a
convenient and effective way to model clinical problems for
patient populations with ongoing risk. The model assumes that
the patient is always in one of a ﬁnite number of states of health,
which in this case were diseased (VLU), healed, and dead [42]. The
model evaluated four separate comparative pathways: standard
care, ECM þ standard care, HSE þ standard care, and LSE þ
standard care.
Weekly cycles were used to examine the costs and outcomes
associated with three Markov health states: unhealed, healed,
and dead (Fig 2). The unhealed state was equated to having a
VLU, and the healed state was equated to having a healed VLU.
The bidirectional arrow between the unhealed and healed states
in the Markov diagram represents ulcer recurrence. Unhealed
was set to a probability of 1 in cycle 0. Costs and clinical
Fig. 2 – Health states of VLUs for Markov modeling. Each
treatment pathway involved three Markov health states:
unhealed, healed, and dead. The unhealed state was
equated to having a VLU, and the healed state was equated
to having a healed VLU. The bidirectional arrow between the
unhealed and healed states in the Markov diagram
represents ulcer recurrence. VLU, venous leg ulcer.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3 805outcomes were calculated for each cycle with no half-cycle
corrections. The ﬁnal model outputs included cumulative costs
(US dollars) and clinical outcomes (ulcer-free weeks) and the
incremental cost-effectiveness ratio (ICER; cost/ulcer-free week)
at 1 year. Modeling ulcer recurrences is difﬁcult because of the
paucity of long-term data, especially beyond 1 year, and thus the
time horizon of 1 year was chosen as a compromise. In addition,
given the relatively high recurrence rate for patients with VLU, a
1-year time horizon was chosen to assess total costs of care.
Infection rates were considered for the Markov analysis. Based
on previous literature [38,39], calculated infection rates for each
month for unhealed ulcers for the ﬁrst 3 months were set at 10%,
with a 5% rate for months 4 to 12. Calculated costs associated
with this rate (cost of antibiotics), however, were low or negligible
(typically 0.1%–0.2% cycle costs); therefore, infection costs were
omitted from the model input.Model Inputs for the Unhealed State
Hospitalizations, debridements, prescription pain drugs, and
home health visits occurred only during the unhealed state.
The percent occurrence for unhealed cost calculations is given
in Table 2. All costs were based on 2012 Medicare national
average reimbursement rates, with the exception of drug costs
for the analgesic medications, which were based on the 2012
Medicaid Survey of National Average Retail Prices (Table 3).Hospitalization
Only hospitalizations speciﬁcally related to VLUs were relevant to
the model. A retrospective cohort study by Olin et al. [11] reported
that approximately 18% of the patients with VLUs were hospi-
talized over a period of 4 months; 7% of the patients underwent
debridement/grafting; and 7% had miscellaneous reasons, includ-
ing bed rest, leg elevation, debridement, antibiotics, dressing
changes, and whirlpool treatments. In the cost-effectiveness
study of Guest et al. [37], it was estimated that approximately10% of the patients with VLUs were hospitalized for 5 days over
the study period of 18 weeks.
Because the hospitalization costs used were based on US
Medicare diagnosis-related groups (DRGs), the following DRGs were
chosen to be representative of VLU visits: DRG 571 (skin debride-
ment with complications and comorbidities), DRGs 602 and 603
(cellulitis with and without major complications), and DRG 593 (skin
ulcers with complications and comorbidities). Hospitalization costs
were incorporated for all unhealed ulcers; if a patient was healed,
there was no likelihood of hospitalization for his or her ulcer. To
calculate the probability of hospitalization rates for DRGs 571 and
593, the data of Olin et al. [11] were extrapolated to 1 year by
calculating the rates for 12 weeks (4.8%), and then assuming half
the rate for weeks 13 to 52 (2.4%), yielding a probability of hospital-
ization for each DRG to be approximately 10% (i.e., 0.10). Rates for
DRGs 602 and 603 were calculated using the following algorithm: (1)
taking the rate of infection reported in the study of Sibbald et al. [38]
over 3 months (i.e., 24%) and extrapolating it to 1 year as follows:
24% (months 1–3) þ12% (months 4–6) þ12% (months 7–12) ¼ 51%,
and (b) using this value, assume that approximately 10% of these
infections would require hospitalization (5% over 1 year), with 20%
having major complications (DRG 602; 1% over 1 year) and 80%
having no complications (DRG 603; 4% over 1 year). It was assumed
that no hospitalizations occurred in the ﬁrst week.
Home Health Care
Mostow et al. [20] reported that 10% of the patients with VLUs
used home health care in the trial, whereas Olin et al. [11] stated
that 27% of their patients with VLUs used home health care. Most
wound care physicians who were consulted stated that approx-
imately 25% to 50% of their patients are referred to home health
care. Consequently, in the base case, 25% of the patients were
selected to have additional home health care with a once-a-week
visit to change the primary dressing as well as the Profore
bandaging (new package). The code C2F2S1, which is 1 visit per
week for a compression dressing change with a 60-day episode of
care, was used for Medicare.
Debridement and Outpatient Visits
Based on considerations from Guest et al. [37], it was estimated
that the probability of debridement per week was 12.5% for the
ﬁrst 12 weeks, which represented a reasonable assumption of
debridement frequency associated with VLU therapy. Centers for
Medicare & Medicaid Services reimbursement rates were used as
a proxy for debridement costs (Table 3). Because of Centers for
Medicare & Medicaid Services reimbursement policy, if debride-
ment occurs, the clinic cannot bill for compression.
The frequency of outpatient (hospital-based outpatient
wound care department) visits was set at 1 visit per week, given
that patients with VLUs typically visit the clinic every week until
the wound is healed. In week 1, the initial clinic visit current
procedural terminology (CPT) code payer costs (Table 3) are used
to generate costs for outpatient visits (i.e., 11042 for debridement
and 99203 for the evaluation and management visit). Because
week 1 is an initial clinic visit, the clinic bills for both the
evaluation and management visit and the debridement proce-
dure. Therefore, week 1 costs for standard care would be
calculated as follows: ($74.88 þ $72.12 þ $59.57 þ $193.02). For
weeks 2 to 12, the CPT code (i.e., 97597) for an established clinic
visit for debridement was used to generate costs. For example, to
calculate the costs generated for weeks 2 to 12 for standard care,
because debridement rates were 0.125 per week, the cost calcu-
lation is as follows: 0.875  ($25.19 þ $78.88) þ 0.125  ($23.83 þ
$104.86). After week 12, because no debridement occurs, only CPT
codes 99212 and 29581 for an established clinic visit for com-
pression were used to generate costs for outpatient visits.
Table 3 – Unit cost table.
Category Item CPT/DRG
code
Medicare costs
($)
Unit and comments
Initial clinic visit Physician, evaluation 99203 74.88 Visit: everything included but
debridementFacility 99213 72.12
Physician, debridement 11042 59.57
Facility, debridement 11042 193.02
Established clinic visit Physician, debridement
Facility, debridement
97597 23.83 Visit; if debridement occurs, then no
compression billing is allowed. If
there is no debridement, the
compression codes are used
because compression is always
done; this means no E/M billing is
permitted.
Physician, compression
only
97597 104.86
Facility, compression only,
Profore
99212 25.19
29581 78.88
Cellular and/or tissue-
derived products
ECM, 3  7 cm, facility Q4102* 152.04 Procedure includes any debridement,
dressing, compression.Physician 15271 87.82
Facility 15271 227.80
HSE, 44 cm2 physician Q4101* 1578.73
Physician 15271 87.82
Facility 15271 227.80
LSE, facility Q4106* 1518.75
Physician 15271 87.82
Facility 15271 227.80
Prescription drugs Amitriptyline 17.30 30  10-mg tablets (15 d)
Gabapentin 98.10 60  300-mg tablets (30 d)
Hydrocodone 30.65 100  10-mg tablets (50 d)
Hospitalization costs Skin debridement with CC 571 8627.00 National averages: 2012; per
hospitalizationCellulitis with major CC 602 8220.00
Cellulitis without major CC 603 4755.00
Skin ulcer with CC 593 5788.00
Home health care costs 1 visit per week for
dressing change
(compression)
C2F2S1 2230.00 Episode of care: 60 d; 2012 ﬁgures
Compression stockings Reimbursable cost A6532 60.00 Per pair (useful life of 6 mo)
Note. A “clinic” is a hospital-based outpatient wound care department.CC, complications and comorbidities; CPT, current procedural
terminology; DRG, diagnostic-related group; ECM, extracellular matrix; E/M, evaluation and management; HCPCS, Healthcare Common
Procedure Coding System code; HSE, human skin equivalent; LSE, living skin equivalent.
* HCPCS code.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3806Prescription Drugs
Only prescription pain medication costs were considered. For the
management of pain associated with VLUs and/or dressing
changes, the following prescription pain drugs were used:1. Amitriptyline: 40% of the patients received 20 mg/d for
unhealed ulcer [39].2. Gabapentin: 10% of the patients received 600 mg/d for
unhealed ulcer [39].3. Hydrocodone: 5% of the patients received 5 mg/d for unhealed
ulcer (based on wound care expert recommendation).
Briggs et al. [43] reported that more than 40% of the patients
with leg ulcers (venous predominant) exhibited neuropathic pain
symptoms. Furthermore, expert opinion conﬁrmed that the
prescription pain drugs included in the model were directly
related to VLU wound pain.
CTP Products
Application rates for each CTP product were taken from the
randomized clinical trials reported in the medical literature
[20,33–35]. ECM was applied once a week for 8 weeks for a total
of 8 applications [20]. HSE was applied once in week 1 and then
1.17 times for weeks 2 and 3 for an average total of 3.34applications [33]. Finally, LSE was applied once a week for weeks
0, 1, 4, and 8 for an average total of four applications [34,35].
Weekly costs for these products are given in Table 4.
Model Inputs for the Healed State
Compression stockings
It was assumed that after healing, patients would wear compres-
sion stockings because this is considered the standard care in the
management of VLUs [16]. The Medicare-allowable cost is $60
(A6532) for a pair of stockings. With useful life set at 6 months for
the base case, the total cost for stockings is $120 per year.
Sensitivity Analysis
Sensitivity analysis is the process of changing the value of an input
parameter to determine the magnitude of its effect on the ﬁnal
results of the analysis. The model enabled deterministic sensi-
tivity analysis on variables of interest. In this analysis, probability
of ulcer recurrence, probability of healing, costs of hospitalization,
home health care, prescription pain medications, compression
stockings, clinic visits, and CTP costs for all products were set at
50% compared with the base case. Outputs were displayed in a
tornado diagram for one-way analyses. A tornado diagram graphi-
cally depicts changes in results relative to changes in model input
Table 4 – Weekly cycle costs in US dollars for each of the interventions.
Cycle number SC (unhealed) ECM þ SC (unhealed) HSE þ SC (unhealed) LSE þ SC (unhealed) Healed
0 470.36 538.45 1965.14 1905.16 –
1 211.00 571.53 2266.60 1938.24 2.31
2 211.00 571.53 2266.60 211.00 2.31
3 211.00 571.53 211.00 211.00 2.31
4 211.00 571.53 211.00 1938.24 2.31
5 211.00 571.53 211.00 211.00 2.31
6 211.00 571.53 211.00 211.00 2.31
7 211.00 571.53 211.00 211.00 2.31
8 211.00 211.00 211.00 1938.24 2.31
9–11 211.00 211.00 211.00 211.00 2.31
12–51 207.92 207.92 207.92 207.92 2.31
ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent; SC, standard care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3 807assumptions and ranks these changes according to their magni-
tude. Variables chosen for sensitivity analyses were those for which
there was substantial uncertainty, expectation of sensitivity, or
recommendation by an advisory body.
In addition, a probabilistic sensitivity analysis was performed
to evaluate parameter uncertainty by using a second-order
Monte-Carlo simulation of 10,000 trials in which all model inputs
were varied simultaneously. This method consists of creating a
“dummy” data set by resampling with replacement (i.e., ran-
domly selecting 1 patient at a time) from the original data set and
repeating this random patient selection until the dummy data set
reaches the same size as the original [44]. The cost-effectiveness
ratio is then recalculated from the dummy data set, and then the
entire process is repeated multiple (e.g., 10,000) times. For
probabilities, beta distributions were applied. Gamma distribu-
tions were applied for assessing variance in costs.Results
Clinical Outcomes
The data in Figure 3 illustrate healed wound weeks among the
CTPs with standard care in relation to standard care alone for the
management of chronic VLUs. Results from the Markov model
indicated that ECM þ standard care had the highest number of
healed wound weeks (31 weeks) followed by HSE þ standard care
(29 weeks), LSE þ standard care (27 weeks), and standard care (24
weeks). To provide a different perspective, the clinical comple-
ment of healed wound weeks is open-wound weeks. Conse-
quently, the number of expected open-wound weeks for ECM þ
standard care, HSE þ standard care, LSE þ standard care, and
standard care is 21, 23, 25, and 28 weeks, respectively. Therefore,
the standard care treatment arm has, on average, 7 additional
open-wound weeks (approximately 2 months) compared with
patients treated with ECM þ standard care, 5 additional open-
wound weeks compared with HSE þ standard care, and 3 addi-
tional open-wound weeks compared with LSE þ standard care.
Wound Closure Rates
The ﬁndings presented in Figure 4 indicate the Markov model–
predicted wound closure rates of VLUs that were treated with
CTPs in adjunct with standard care in relation to standard care
alone. Among the CTP treatment approaches, ECM þ standard
care achieved the highest wound closure rate (75%) follow-
ed by LSE þ standard care (70%) and HSE þ standard care (69%).
Standard care had the lowest wound closure rate (66%).
With higher rates of wound closure, patients will incur lessdownstream long-term costs (i.e., hospitalization, home health,
outpatient visits, and prescription pain drugs).
Cost-Effectiveness
The ﬁndings presented in Table 4 indicate that weekly cycle costs
vary considerably on the basis of product usage patterns obtained
from the CTPs clinical trials. Although wound closure was similar
among the three CTPs, upfront costs for the application of the
product are substantially higher for HSE ($1578) and LSE ($1518)
than for ECM ($152), a difference of approximately $1400. Figure 5
illustrates the estimated cumulative costs among three CTP
therapy approaches in the management of chronic VLUs. Markov
modeling predicted that the LSE þ standard care treated group
incurred the highest cumulative costs per VLU ($11,237) followed
by HSE þ standard care ($10,638), ECM þ standard care ($6,732),
and standard care ($6,132) treated groups.
Results in Table 5 indicate the estimated total direct costs (US
dollars) and cost-effectiveness of various treatment strategies in
the management of chronic VLUs compared with standard care.
Markov modeling results indicated that relative to standard care,
the LSE þ standard care treated group incurred the highest
incremental costs per VLU ($5104), followed by HSE þ standard
care ($4505) and ECM þ standard care ($599). Patients treated with
ECM þ standard care had the least expensive cost-effectiveness
ratio ($217) compared with standard care ($256), HSE þ standard
care ($367), and LSE þ standard care ($416). Overall, these ﬁndings
reveal that ECM þ standard care was economically dominant
with lower total costs ($3906 compared with HSE þ standard
care and $4505 for LSE þ standard care) and better clinical
outcomes (2 more ulcer-free weeks compared with HSE þ stand-
ard care and 4 more ulcer-free weeks compared with LSE þ
standard care) compared with the other two CTPs. The ICER for
ECM þ standard care relative to standard care was approximately
$86 per ulcer-free week. This indicates that if a patient is willing
to pay an additional $86 (approximately $12/d), he or she can gain
one additional ulcer-free week.
Sensitivity Analysis
The output of a series of one-way sensitivity analyses is dis-
played as a tornado diagram. Figure 6 illustrates the results of
analyses comparing costs for resource utilization and probabil-
ities of healing and ulcer recurrence across the CTPs and stand-
ard care. The base-case value was $6133, which was the overall
cost for standard care. ECM product cost and probability of
healing on ECM weeks 1 to 12 had a large effect on the expected
total costs, especially when the costs were lower than standard
care. The cost of clinic visits from weeks 13 to 52 exerted the
F
r
s
Fig. 3 – Comparison of healed wound weeks among SC and three cellular/tissue-derived product treatment approaches in
relation to SC for the management of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living
skin equivalent; SC, standard care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3808greatest inﬂuence on expected total costs in the analysis. The
second most sensitive input was home health care. The next
most sensitive inputs were the probability of healing for standard
care in weeks 1 to 12 and the probability of healing for ECM in
weeks 13 to 26. Although all CTP products were analyzed in the
sensitivity analysis, ECM was the only product that had aig. 4 – Comparison of expected wound closure rates among thre
elation to SC for the management of venous leg ulcers. ECM, ex
kin equivalent; SC, standard care.potential effect on expected total costs. ECM was the only CTP
with similar costs to standard care; therefore, price variations
would be more sensitive. In addition, all model inputs were
considered in the sensitivity analysis; however, if an input did
not appear in the tornado diagram, this indicates that it did not
have a large effect on the expected total costs. The values ofe cellular/tissue-derived product treatment approaches in
tracellular matrix; HSE, human skin equivalent; LSE, living
Fig. 5 – Comparison of cumulative costs among three cellular/tissue-derived product treatment approaches in relation to SC
for the management of venous leg ulcers. ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin equivalent;
SC, standard care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3 809these inputs were derived from CPT codes for 2012 Medicare-
allowable total expected costs. The sensitivity analysis results did
not change the dominance of ECM over other CTP products.
Results from the probabilistic sensitivity analysis demonstrate
that costs for standard care and ECM þ standard care were
consistently the lowest among the four treatments (Fig. 7). Each
point in the scatterplot represents one bootstrap iteration. ECM þ
standard care had the highest average effectiveness of 31  6.2
ulcer-free weeks, whereas standard care had the lowest at 24 
5.1 ulcer-free weeks (Table 6).Discussion
Overall, results from this study demonstrated that ECM as an
adjunct therapy to standard care was the most cost-effective at
$86 per ulcer-free week when compared with other CTPs over a
period of 1 year. This indicates that an individual would have to
pay approximately $86 more per week (approximately $12/d) to
gain an additional ulcer-free week relative to standard care alone.
Clinic visits for weeks 13 to 52 and home health exerted the
greatest inﬂuence on expected total costs. The base caseTable 5 – Total costs* and cost-effectiveness of various t
venous leg ulcers.
Strategy Cost ($) Incremental
cost ($)
Effectivenes
SC 6,133 24
ECM þ SC 6,732 599 31
HSE þ SC 10,638 4,505 29
LSE þ SC 11,237 5,104 27
ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin
* Costs are based on Medicare maximum allowable reimbursements.represents one set of assumptions expressed in terms of proba-
bilities, unit of resource use, and unit cost inputs to the model.
Using the Markov model, when the ECM adjunct therapy was
compared with the HSE or LSE therapy, the ICERs for ECM were
dominant in the base cases. The expected number of open-
wound weeks for ECM þ standard care was 21 weeks. The
standard care treatment arm had, on average, 7 additional
open-wound weeks (approximately 2 months) compared with
patients treated with ECM þ standard care, 5 additional open-
wound weeks compared with HSE þ standard care, and 3 addi-
tional open-wound weeks compared with LSE þ standard care.
These additional open-wound weeks can have substantial clin-
ical, economic, and humanistic impact on patients. The longer a
wound remains unhealed, the greater the risk of infection, risk of
amputation, additional costs of care, and decreased quality of life
[1–4]. Closing the wound several weeks earlier using ECM as an
adjunct to standard care could help reduce downstream impli-
cations and cost of care for VLUs.
There is a lack of rigorous investigations examining the
economic burden of treatments for the management of VLUs.
The existing studies of economic analyses of VLUs have been
described as unsophisticated, consisting of only summing thereatment strategies in the management of chronic
s Incremental
effectiveness
Incremental
cost/
effectiveness ($)
Cost/
effectiveness ($)
256
7 86 217
5 901 367
3 1701 416
equivalent; SC, standard care.
Fig. 6 – Tornado diagram demonstrating the inﬂuence of parameter uncertainty on the expected cost of therapy. ECM,
extracellular matrix; SC, standard care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3810monetary cost of the dressings [45]. With regard to cost-effective-
ness, there are limited studies that examine leg ulcer treatment.
This work was one of the ﬁrst to investigate the cost-
effectiveness of three different CTPs in the management of VLUs.
Furthermore, this study used detailed Medicare-allowable costs,
hospitalization costs, wound healing trajectories and ulcer recur-
rence cross-checked against trial wound-healing trajectories, and
a Markov modeling process that used a 1-week cycle time over a
period of 1 year.
Because of a wide variety of methodological approaches,
modeling the direct cost of ulcer therapy in conjunction with
healing trajectories can be challenging, especially when account-
ing for therapy regimens with CTPs. Previous cost-effectiveness
analyses have found similar results when assessing the relative
costs and beneﬁts of CTPs in the management of VLUs. Schonfeld
et al. [31] evaluated the cost-beneﬁt of HSE in comparison to
Unna’s boot as the standard care using a semi-Markov model
over a horizon time of 1 year and found that rates of healing in
the HSE group were approximately 48.1% compared with 25.2% in
standard care patients. Annual costs for HSE patients were
slightly more expensive than the annual cost for Unna’s boot
patients ($12,807 vs. $10,482, respectively; 1996 US dollars), with a
calculated ICER of $800 per additional month of healing. Results
from this study are consistent with these ﬁndings.
Similar results were found in a study conducted by Hankin
et al. [5] who evaluated and compared the clinical and cost
efﬁcacy of ECM, HSE, and Talymed as an adjunct to standard
care compared with standard care alone for the treatment of
chronic VLUs. In this study, investigators considered only product
cost and beneﬁt in terms of the number needed to treat.
The study is unique and is based on a different method com-
pared with other cost-effectiveness studies in wound caremanagement. Despite these challenges, the study found that
the ICERs per additionally successfully treated patient were
$1,600 for Talymed, $3,150 for ECM, and $29,952 for HSE after 24
weeks. Results from this study for ECM at 24 weeks ($3366)
agree with ﬁndings from this study.
In another study, Harding et al. [46] utilized an expert
panel to compare the clinical outcomes and resource utilization
of HSE with standard care (compression, two dressing types). The
study included the devised protocols of care using saline-gauze,
Granuﬂex, and HSE as adjuncts to standard care therapy (i.e.,
debridement and compression bandaging). The estimated costs
(1999 British pounds) per ulcer healed were £541 for saline-gauze,
£342 for Granuﬂex, and £6741 for HSE. Although these ﬁndings
utilized a different outcome and assessed cost per ulcer,
this method of analysis did not account for the cost of un-
healed ulcers, which could yield bias results. Similar argu-
ments can be made for other studies that previously reported
the cost-effectiveness of wound management protocols of care
[30,47].
In a decision-analytic approach randomized study by Sibbald
et al. [38], a cohort of 1000 patients modeled over 3 and 6 months
compared the clinical outcomes of HSE versus standard care
(four-layer compression). The investigators felt that using four-
layer bandage compression was more realistic and enlisted the
help of a Delphi panel to assist with resource utilization and
clinical outcomes. These investigators, however, used only one
application of HSE. From the health care perspective, costs at 3
months were $1701 for HSE versus $1386 (Canadian dollars) for
standard care, with an ICER of $98 (Canadian dollars) per ulcer-
free week. The premise of a single application of HSE (based on a
small case series conducted by the lead author) is susceptible to
bias because changing the number of applications will likely
Fig. 7 – Probabilistic sensitivity analysis by treatment. Each point on the plot corresponds to one trial in the Monte-Carlo
simulation comparing the incremental effectiveness and incremental costs of therapy. Costs for SC and ECM were
consistently the lowest and effectiveness the highest for the treatment of venous leg ulcers. ECM, extracellular matrix; HSE,
human skin equivalent; LSE, living skin equivalent; SC, standard care.
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in favor of HSE. Together, the ﬁndings of these studies indicate a
large variation in costs that cannot always be compared because
the units cannot be converted in a meaningful way to a
common basis.
Effective management of VLUs remains difﬁcult and con-
sumes a substantial amount of resources such as medical and
nursing time, cleansing solutions, other topical applications,
dressing products, analgesics, bandages, hospitalization, and
compression stockings. Moreover, treatment of VLUs is spread
across many areas of health care in both the United States and
Europe [36,37,48,49]. The total costs of treatment for VLUs
comprise 2% of total annual health care expenditures for WesternTable 6 – Probabilistic sensitivity analysis: Monte-Carlo
Result SC EC
Effectiveness, mean  SD 23  5
Effectiveness minimum 6
Effectiveness 2.5% 14
Effectiveness median 23
Effectiveness 97.5% 33
Effectiveness maximum 42
Cost ($), mean  SD 6,284  1,609 6,98
Cost minimum ($) 2,161
Cost 2.5% ($) 3,685
Cost median ($) 6,099
Cost 97.5% ($) 9,909
Cost maximum ($) 16,108
ECM, extracellular matrix; HSE, human skin equivalent; LSE, living skin
* Effectiveness measure was ulcer-free weeks.European countries [49]. Treatment modalities for VLUs in The
Netherlands consist of conservative treatment (i.e., compression
therapy, local treatment, and leg elevation) and surgical treat-
ment (i.e., superﬁcial and perforating vein ablation and deep vein
reconstruction) [36]. Because of limited access to advanced
therapies, investigators in The Netherlands suggest that surgery
combined with ambulatory compression therapy is an effective
treatment modality for VLUs [48], which could escalate costs.
TennVall and Hjelmgren [48] found that total costs of health
states as well as for different ulcer types were generally higher in
Sweden than in the United Kingdom, with labor accounting for
most of the cost in both countries. Distinct differences exist in
resource utilization regarding treatment strategies for VLUs [37].simulation results*.
M þ SC HSE þ SC LSE þ SC
30  6 27  7 26  6
7 6 8
17 12 15
30 27 26
41 40 37
46 46 43
1  2,240 10,932  3,013 11,491  3,679
1,707 2,741 3,253
3,356 5,849 5,707
6,722 10,656 10,993
11,988 17,486 19,996
19,135 26,642 30,771
equivalent; SC, standard care.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 0 1 – 8 1 3812Guest et al. found that in Germany, hospitalization was the
primary cost driver for VLUs, whereas drugs and ofﬁce nurse
visits were the primary cost driver in the United States. Despite
differences in resource utilization and treatment approaches,
health care expenditures and rates of healing for VLUs are similar
[37]. Although CTPs are rarely used in Europe, similar costs and
outcomes support the argument that conventional therapy may
need to be supplemented by other options, such as the use of
CTPs, in an attempt to overcome the pathophysiological prob-
lems of chronic wounds.
Certain limitations should be considered when interpreting
the ﬁndings of this study. First, although ulcer sizes at baseline
were comparable between ECM and LSE trials [20,34,35], ulcer
sizes were much smaller in the HSE trial [33]. This suggests that
the analysis is likely to be biased in favor of HSE. In addition, no
data are available with regard to the healing rates for ECM or HSE
at different application rates and only limited data are available
in the case of LSE. Moreover, the cost-effectiveness model did not
track the cycle at which an ulcer recurrence occurs to avoid
microsimulation, which may cause a small inaccuracy in costs
proportional to the recurrence rate. Finally, modeling and param-
eter uncertainty occurs with most of the models. A limitation of
the Markov model is that the probability of moving out of a
particular health state is not dependent on the states a patient
may have experienced before entering that speciﬁc health state [50].
With the use of time-dependent transition probabilities, however,
this limitation is minimized. Furthermore, parameter uncertainty
was reduced by conducting deterministic and probabilistic sensi-
tivity analyses. Nevertheless, the ﬁndings of this study provide
critical information on the clinical and cost-effectiveness of differ-
ent CTPs used as adjunct therapies in the management of VLUs.
Future RCTs should focus on a multiarm approach in which
advanced therapies can be tested simultaneously.
In conclusion, ECM adjunct therapy was cost-effective when
compared with standard care in the management of VLUs. When
compared with HSE or LSE, the cost-effectiveness of ECM was
dominant. In other words, when using the application rates as
reported by the respective RCTs, ECM provided better clinical
outcomes (i.e., ulcer-free weeks) at a substantially lower cost.
Currently, health insurance plans restrict coverage and reim-
bursement of CTPs to patients who have failed compression
therapy. Earlier treatments with CTPs in patients with VLUs,
even though initially more expensive, may be more efﬁcacious
and less costly in the long term. Results from this study support
this outcome. Head-to-head clinical trials comparing CTPs for the
treatment of VLUs are warranted to establish efﬁcacy. In addition,
decision analysis is an important preliminary to the design of a
prospective economic evaluation alongside a clinical trial
because modeling can identify critical variables appropriate to
the economic analysis. Decision analysis may be helpful in
optimizing resource allocation in the treatment and management
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